Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery; Neurotech reassures ASX by Steve Jones April 29, 2026April 29, 2026 Avecho Biotechnology dosed 244 patients in its phase III insomnia trial, 16% above target, in a […]
Sandoz over-the-counter CBD deal ‘remarkable’, Avecho chair tells AGM by Steve Jones May 28, 2025May 28, 2025
Avecho turns to new investors to raise funds for CBD clinical trial by Steve Jones May 9, 2023April 30, 2024
Company news: Cann Global; Elixinol; Bod Science; AusCann; IvyMed Clinic; Botanix by Steve Jones and Martin Lane April 5, 2023April 30, 2024
Emyria strikes commercial deal with Aspen for over-the-counter product by Steve Jones April 4, 2023April 30, 2024
Ecofibre becomes second company to confirm disappointing sleep trial results by Steve Jones January 30, 2023March 13, 2023
Sleepless nights ahead for Cann Group as over-the-counter CBD trial fails the placebo challenge by Steve Jones January 19, 2023January 19, 2023
Cann Group poised to scale-up production after securing A$8.2m from shareholders by Steve Jones December 5, 2022April 29, 2024
Bod strikes CBD over-the-counter deal with pharma firm Arrotex by Steve Jones December 2, 2022April 29, 2024
